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Suppression of glucagon by adjunctive agents  
Galderisi A et al 
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Context. Postprandial hyperglycemia remains a challenge in type 1 diabetes (T1D) due, in part, 
to dysregulated increases in plasma glucagon levels after meals.  
Objective. This study was undertaken to examine whether 3-4 weeks of therapy with pramlintide 
or liraglutide might help to blunt postprandial hyperglycemia in T1D by suppressing plasma 
glucagon responses to mixed meal feedings. 
Design. Two parallel studies were conducted in which participants underwent mixed meal 
tolerance tests (MMTTs) without premeal bolus insulin administration before and after 3-4 
weeks of treatment with either pramlintide (8 participants aged 20±3yrs, A1C 6.9±0.5%) or 
liraglutide (10 participants aged 22±3yrs, A1C 7.6±0.9%).  
Results. Compared to pre-treatment responses to the MMTT, treatment with pramlintide reduced 
the peak increment in glucagon from 32 ± 16 to 23 ± 12 pg/mL (p<0.02).  In addition, the 
incremental area under the plasma glucagon curve from 0-120 minutes(Glucagon iAUC0-120 min) 
dropped from 1988±590  to 737±577 pg/mL*min (p<0.001), which was accompanied by  a 
similar reduction in the meal-stimulated increase in the plasma glucose curve (Glucose iAUC 0-
120 min) from 11963±1424mg/dL*min pre-treatment vs 2493±1854 mg/dL*min after treatment 
(p<0.01). In contrast, treatment with liraglutide had no effect on plasma glucagon and glucose 
responses during the MMTT. 
Conclusions: Adjunctive treatment with pramlintide may provide an effective means to blunt 
post-meal hyperglycemia in T1D by suppressing dysregulated plasma glucagon responses. In 
contrast, plasma glucose and glucagon responses were unchanged after 3-4 weeks of treatment 
with liraglutide. 
We examined the effect of pramlintide or liraglutide as adjunctive therapy on postprandial glucagon and 
glucose response to mixed meal feedings in youths with type 1 diabetes. 
1. Introduction 
Postprandial hyperglycemia remains a challenge in type 1 diabetes (T1D) due to a number of 
factors that include delays in the absorption and action of pre-meal boluses of insulin from the 
subcutaneous space and dysregulated glucagon secretion in response to mixed meal feedings.(1-
5) In non-diabetic individuals, plasma glucagon levels change very little after eating a mixed 
meal that includes protein and carbohydrate because the stimulation of glucagon secretion by 
increases in plasma amino-acids is off-set by the suppression of glucagon secretion by increases 
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in plasma glucose levels. In contrast, it has been demonstrated that children with type 1 diabetes 
have higher plasma glucagon responses after a mixed meal feedings compared to healthy peers. 
(3) Moreover, plasma glucagon responses to mixed meal feeding increase over time, presumably 
due to the progressive loss of residual β-cell function. (1,6) 
 Due to the adverse impact of postprandial hyperglycemia on overall glycemic control and 
on the risk of complications, (7,8) it has been suggested that treatment with agents approved for 
use in T2D may be effective in lowering post-prandial glucose peaks in T1D  by mechanisms 
independent of stimulation of insulin secretion (9,10). Specifically, SGLT2 inhibitors reduce 
plasma glucose by lowering the renal threshold for glucose excretion; (11) whereas, it has been 
suggested that the glucose-lowering effects of both pramlintide (an analog of amylin) and 
liraglutide (a GLP1 agonist) are due, in part, to slowing of gastric emptying and suppression of 
exaggerated post-meal increases in plasma glucagon. (12,13)  In two parallel studies, we used a 
full-closed loop insulin delivery system to control post-meal glucose excursions before and after 
3-4 weeks of treatment with pramlintide and liraglutide at maximally recommended doses. Those 
studies showed durable slowing of gastric emptying with pramlintide but not with liraglutide. 
(14) In those studies, we also performed mixed meal tolerance tests (MMTTs) in the morning 
following 24-hours of closed–loop control to examine and compare whether after 3-4 weeks of 
treatment with  pramlintide or liraglutide suppressed meal-stimulated  increases in plasma 
glucagon in T1D. (14) The results of these MMTTs are reported herein.  
2. Material and Methods 
A. Participants 
Participants were eligible to enroll in the pramlintide and liraglutide studies if they had a clinical 
diagnosis of type 1 diabetes for at least 1 year, A1c ≤9% (≤75mmol/mol) and a normal 
hematocrit and serum creatinine level. Participants were excluded if they had a history of an 
eating disorder, celiac disease, gastroparesis, another disorder of intestinal absorption or motility, 
a history of a hypoglycemic seizure in the past 3 months, another chronic medical condition 
(except treated hypothyroidism), current use of medications (other than insulin) known to affect 
blood glucose level or gastrointestinal motility and prior adverse reactions to the drug under 
study. Female participants could not be pregnant or lactating. The studies were reviewed and 
approved by the Yale University Human Investigation Committee and written informed consent 
was obtained by adult participants. Parental consent with participant assent were obtained for 
participants <18 years.  
B. Procedures 
Dose Titration Phase:  
Participants in the studies underwent two 24 hour periods of closed-loop glucose control before 
and after 3-4 weeks of treatment with pramlintide or liraglutide. (14) During outpatient 
treatment, the dose of pramlintide was uptitrated from 30 to 60 ug given 15 minutes prior to each 
meal and the once daily dosing of liraglutide before breakfast was uptitrated from 0.6 to 1.8 
mg/day. In both studies, insulin doses were adjusted, as needed, by frequent telephone contacts 
with the study participants. 
Mixed Meal Tolerance Tests (MMTTs):  
In each study, the participants underwent two mixed meal tolerance tests, the first performed 
before therapy with pramlintide or liraglutide and the second performed after 3-4 weeks of 
treatment with one of the drugs. All MMTTs were performed at ~8 AM in the morning after an  
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3
8-12 hour overnight fast, during which glucose levels were regulated with a Medtronic closed-
loop system. (14)  The CL system used in both of these studies consisted of four components: a 
Medtronic Paradigm 715 insulin pump, a Medtronic MiniLink REAL-Time transmitter (MMT- 
7703) adapted for 1-min transmission, a Medtronic continuous glucose sensor (Sof-sensor in the 
pramlintide study and Enlite sensor in the liraglutide study), and the Medtronic external 
Physiological Insulin Delivery (ePID) algorithm modified to include insulin feedback, which was 
on a laptop computer. 
 An intravenous catheter was used for frequent blood sampling during the MMTTs. At the 
start of the 4 hour MMTTs, baseline samples for measurement of plasma glucose and plasma 
glucagon were obtained, the closed loop system was shut-off and participants were placed back 
on their usual open loop basal rate settings. Participants then consumed 6ml/kg of Boost High 
Protein 6cc/kg to a maximum dose of 360mL.  Additional blood samples for measurements of 
plasma glucose and plasma glucagon were obtained every 15-30 min for 240 minutes following 
ingestion of Boost High Protein; (3) the macro-nutrient content per100 ml of Boost High Protein 
is protein 6.3g, carbohydrate 13.9g and  fat 2.5g. During the second MMTT for each participant, 
pramlintide (60 mcg) or pramlintide (1.8 mg) was injected just prior to meal ingestion. 
The primary outcome of the two parallel studies reported here was the difference in the 
incremental area under the curve in plasma glucagon levels from baseline to 120 min (Glucagon 
iAUC0-120 min). Secondary outcomes included the Glucagon iAUC 120-240 min, Glucose  iAUC0-120 min 
and Glucose iAUC 120-240 min, changes in peak plasma glucagon and peak plasma glucose levels 
and the time-to-peak for glucagon and glucose over 240 minutes.  
Breakfast during closed loop.  
Participants in the liraglutide group had their glucagon and glucose response to breakfast 
assessed during the 24-hr closed loop admissions. Meals were self-selected and were not limited 
by calorie or carbohydrate content. Samples were obtained every 15-30 min for 180 minutes 
after the breakfast to assess both glucose and glucagon levels. Closed loop insulin delivery was 
maintained during the meal test. 
C. Laboratory measurements  
Plasma glucose was analyzed using the YSI 2300 STAT Plus glucose analyzer (YSI Life 
Sciences, Yellow Springs, OH). Glucagon was measured by a double antibody 
radioimmunoassay (EMD Millipore, RIA assay, GL-32K).  The lower limit of detection of 
plasma glucagon was 20 pg/mL and the higher limit of the standard assay curve was 400 pg/mL. 
The accuracy of the assay was 97±0.8%. 
D. Statistical Considerations 
Comparisons between the pre- and during treatment measurements were calculated using paired t 
Student test for continuous variables. Fisher exact test was adopted for categorical variables. 
Changes in plasma glucose and glucagon during the MMTTs were expressed as incremental 
values from baseline (0 minutes) to the specified timepoints. The incremental areas under the 
curve (iAUC) and the peak value for both plasma glucose and glucagon were calculated as 
difference from the baseline measure (0 minutes). Data are expressed as mean±SD. Data were 
analyzed using GraphPad Prism 7 software (GraphPad Software, Inc., La Jolla, CA). 
3. Results 
A. Participants  
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Ten out of 11 participants who enrolled in the CL study (14) with liraglutide agreed to undergo 
the two MMTTs, as did 8 of 10 participants from the pramlintide study. The clinical 
characteristics of the 10 liraglutide and 8 pramlintide participants are shown in Table 1. 
 B. MMTT Results 
B1. Baseline plasma glucagon and glucose levels 
As shown in Table 2, in each of the experiments, overnight CL insulin delivery resulted in 
baseline fasting plasma glucagon and glucose levels that were similar in both groups of subjects 
both before and during treatment with pramlintide and liraglutide.  
B2. Increments in plasma glucagon and glucose before and during treatment with pramlintide 
The patterns of incremental changes in plasma glucagon and glucose before and during treatment 
with pramlintide are shown in Figure 1A and 1B, respectively. During the first 2 hours of the 
MMTTs, treatment with pramlintide markedly reduced the rise in plasma glucagon levels 
following meal ingestion (Figure 1A) and increases in plasma glucose levels were also blunted 
(Figure 1B). Moreover, between 2-4 hours, glucagon levels remained suppressed during 
treatment with pramlintide (Figure 1A), even in the face of a delayed rise in plasma glucose 
levels (Figure 1B). As shown in Table 3, adjunctive therapy with pramlintide markedly 
suppressed the glucagon iAUC
 0-120 min and the peak increment in plasma glucagon, as well as the 
glucose iAUC
 0-120 min,  Glucose iAUC 120-240 min and the peak increment in glucose. Pramlintide 
treatment also delayed the time to peak glucagon and glucose levels. (Table 3).  
B3. Increments in plasma glucagon and glucose before and during treatment with liraglutide 
 The incremental changes in plasma glucagon and glucose before and during treatment 
with liraglutide are shown in Figure 1C and 1D. As seen in these Figures, after 3-4 weeks of 
liraglutide treatment, there were no significant differences in the plasma glucagon and glucose 
responses during the first 120 min and second 120 min following Boost ingestion. As shown in 
Table 3, the peak increment in plasma glucagon, the time to peak glucagon and the iAUC for 
glucagon were not significantly different before and during treatment with liraglutide. 
Furthermore, there were no significant changes in the peak increment in plasma glucose, time to 
peak glucose and iAUC for glucose after treatment with liraglutide. 
C. Plasma glucagon and glucose responses during closed loop insulin delivery before and during 
treatment with liraglutide  
 To validate that a liquid meal response would be reflective of the physiologic changes in 
glucagon and glucose following a standard meal under controlled insulin delivery conditions, a 
self-selected breakfast was provided to participants during both closed loop admissions. The 
average macronutrient content of the standardized breakfast was 75 ± 49 grams of carbohydrates, 
24 ± 16 grams of protein, and 17 ±14 grams of fat. Corroborating the findings demonstrated 
during the MMTT, no difference in the glucagon or glucose response was appreciated in the 3-
hours following the standardized breakfast meal (Figure 2 and Supplemental Table). 
4. Discussion 
Pramlintide and liraglutide have been widely investigated as adjunctive therapies aimed at 
limiting post-meal hyperglycemia in T1D (9,12,14-25) due to putative modes of action that 
include the ability to suppress dysregulated glucagon responses to mixed meal feedings, slowing 
of gastric motility and earlier satiety. (9,26,27) It should be noted, however, that clinical studies 
have demonstrated differences between the two drugs on glucose control, glucagon secretion and 
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gastric emptying (14,16,18,19,22,28-30) with liraglutide surprisingly increasing the glucagon 
responses to mixed meal feedings after chronic treatment in type 2 diabetes and pramlintide 
being highly effective in delaying gastric emptying but with conflicting effects on glucagon 
secretion in T1D. (14,24)  
Our parallel studies of the use of pramlintide and liraglutide as adjunctive agents to improve 
control of post-prandial glucose excursions during closed-loop insulin delivery provided a 
unique opportunity to examine and compare the effects of these agents on dysregulated increases 
in plasma glucagon levels after meals. (14) Consequently, the most important findings of the 
current study are that we were unable to observe any suppressive effects of liraglutide on plasma 
glucagon responses to mixed meal feedings or any suggestion of a delay in gastric emptying after 
only 3-4 weeks of treatment. In contrast, marked suppression of 2-hour-plasma glucagon, as well 
as reduced and delayed increases in plasma glucose levels were sustained after the same duration 
of treatment with pramlintide.  
These findings are consistent with previous studies that supported approval of pramlintide for 
use as an adjunctive agent in T1D (12,22,23,30,31) and more recent phase 3 studies of liraglutide 
that indicted little improvement in metabolic control in patients with T1D. (16,17,20) Our results 
are also consistent with previous reports, indicating that liraglutide is a less effective drug of its 
class in modulating the gastric motility, with more pronounced action from short-term GLP-1 
analogues, like exenatide or lixisenatide. (26,32) As noted in our previous publication in this 
groups of patients (24) and by others, (19,33) liraglutide may be of benefit to overweight or 
obese patients with T1D due to its suppression of appetite, which may support weight loss and 
reductions in insulin doses.(17,27) 
A strength of the study, is that the MMTTs were performed after completion of 24 hours of 
closed-loop insulin delivery, including overnight control just prior to the start of the MMTTs 
with the last meal being consumed >12 hours earlier. Most MMTT protocols mandate that 
fasting glucose levels between 70-200 mg/dL be achieved prior to meal ingestion. Our use of the 
closed loop system ensured that participants had even tighter glycemic control, thus minimizing 
the potential confounding effects of differences in fasting plasma glucose prior to performance of 
the procedure. Even plasma glucagon levels were similar prior to the conduct of the pre- and 
post-treatment MMTTs performed. Use of the closed-loop system also ensured precision in 
regards to the insulin delivery prior to the start of the MMTTs, eliminating a potential 
confounding factor of overinsulinization prior to meal ingestion. Thus, in both sets of 
experiments, the only difference between the two MMTTs in each participant was the injection 
of the study drug prior to the second MMTT.    
Compared to the sharp increases in plasma glucagon and plasma glucose during the pre-
treatment MMTT, only a slight increase in plasma glucagon and glucose levels was observed 
during the first 60 minutes of the MMTT during treatment with pramlintide. (Figure 1D) 
However, it is possible that diminished increases in plasma glucagon and plasma glucose during 
the first 2 hours of the MMTT were both due to delays in gastric emptying rather than by 
suppression of glucagon secretion by pramlintide. Arguing against this conclusion is the 
observation that the relatively flat glucagon response following meal ingestion with pramlintide 
was present for the full 4-hours of the MMTT, despite delayed absorption of carbohydrate and 
amino-acids and corresponding increases in plasma glucose after meal ingestion. These data 
suggest that the ability of pramlintide to mitigate post-meal hyperglycemia is related to both its 
ability to delay gastric emptying and to suppress α-cell secretion. 
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A limitation of the present study was that it was not designed to allow for formalized 
comparison between the two agents.  However, comparison of the individual treatments prior to 
and post treatment in the two separate cohorts studied allows extrapolation of how the two 
adjunctive therapies may differ.  It should also be noted that studies examining physiologic 
changes induced by pharmacologic agents often have larger sample size. However, the present 
analysis is a sub-study nested within inpatient closed-loop studies that were designed to examine 
the feasibility and potential efficacy of adjunctive therapies in conjunction with closed-loop 
insulin delivery.  Although our sample size is relatively small, it was sufficient to show a change 
in hormonal response during treatment with pramlintide.  While we have no direct means of 
assessing participants’ compliance in taking the study drugs during the outpatient phase of the 
studies, paricipantts were contacted frequently by telephone during this time.  These phone calls 
allowed investigators to encourage compliance and assess for adverse effects of the study 
medications.  Importantly, all participants in both studies tolerated the full therapeutic doses of 
the drugs during the inpatient studies, which would have been unlikely if they had not been 
compliant in the outpatient dose titration phase. Finally, as a surrogate marker for compliance, it 
is notable that during both studies participants on average had a lowering of their total daily 
insulin dose. (24) 
Finally, it is possible that use of a standardized meal instead of a liquid mixed meal would 
have provided better approximation of how these therapies impact day-to-day life. Although not 
performed in the pramlintide study, plasma glucagon responses to a standardized breakfast 
during closed-loop insulin delivery was assessed in the liraglutide study.  Furthermore, the 
standard breakfast meal study conducted during the inpatient closed loop admissions provided 
the opportunity to see if dynamic insulin delivery impacted the results of meal-stimulated 
glucagon and glucose responses.  As demonstrated in the Figure 2, no difference was 
appreciated with the standard meal; thus, providing justification for assessment of the MMTT in 
the present analysis. (Supplemental Table 1) and confirming the reliability of the use of 
MMTT, instead of a real meal, to assess the effect of the adjunctive therapy on glucagon and 
glucose response. 
 In conclusion, this study has highlighted that liraglutide did not suppress dysregulated 
increases in plasma glucagon responses to meals even after a relatively short period of treatment. 
We have also confirmed the effect of pramlintide in limiting the early meal-stimulated increases 
in plasma glucagon and glucose levels. However, the requirement for subcutaneous injections of 
pramlintide before each meal has limited the use of this agent in patients with T1D in clinical 
practice.   
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Figure 1. Glucose and glucagon profile during mixed meal tolerance test. Glucose profile 
before and after the treatment with liraglutide (1A) and pramlintide (1B) during mixed meal 
tolerance test; Glucagon profile before and after the treatment with liraglutide (1C) and 
pramlintide (1D) during mixed meal tolerance test. Glucose and glucagon are expressed as 
incremental value from the baseline. 
Figure 2. Change in glucose and glucagon levels during full closed loop insulin delivery with a 
standardized breakfast prior to and 3-4 weeks post treatment with liraglutide. 
Table 1 Baseline characteristics 
 Liraglutide (n=10) Pramlintide (n=8) p 
Clinical Characteristics    
Sex (F/M) 6/4 5/3 >0.99 
Age (y) [age range] 21.9±3.5 [18-27] 19.6±2.8 [16-23] 0.151 
BMI (kg/m2) 23.5±2.9 23.0±1.5 0.665 
HbA1c at enrollment % (mmol/mol) 7.5±1.0 (58.0±10.9) 6.9±0.5 (52.0±5.5) 0.142 
Diabetes’ duration (y) 9.9±6.5y 9.4±4.6y 0.857 
Weight (kg) 67.1±9.6 70.7±14.6 0.537 
Total daily insulin dose (U/kg/day) 0.8±0.1 0.9±0.3 0.355 
Notes: Data are means (SD) unless otherwise indicated. 
Table 2. Baseline glucose and glucagon values prior to and post treatment with adjunctive 
therapy. 
Pramlintide 
 Pre-Treatment Post-treatment p-value 
Glucose (mg/dL) 121 ± 22 115± 21 0.586 
Glucagon (pg/mL) 42 ± 22 45 ± 19 0.775 
Liraglutide 
 
Pre-treatment Post-treatment p-value 
Glucose (mg/dL) 100 ± 16 116 ± 27 0.124 
Glucagon (pg/mL) 52 ± 19 47 ± 19 0.563 
Notes: Data are means (SD) unless otherwise indicated. 
Table 3. Outcomes measures                                                                                                                 
 Liraglutide Pramlintide 
Glucagon Pre-treatment Post-treatment p Pre-treatment Post-treatment p 
Glucagon iAUC0-120 
(pg*min/ml) 1904 ± 651 1801 ± 906 0.774 1988 ± 590 737 ± 577 0.0007 
Glucagon iAUC120-240 
(pg*min/ml) 311 ± 564 701 ± 860 0.246 560 ± 807 933 ± 789 0.366 
Glucagon incremental 
peak(pg/ml) 29 ± 16 35 ± 20 0.309 32 ± 16 23 ± 12 0.026 
Glucagon time-to-peak (min) 47 ± 30 64± 41 0.281 49 ±22 173 ± 66 0.0097 
Glucose Pre-treatment Post-treatment p Pre-treatment Post-treatment p 
Glucose iAUC0-120 
(mg*min/dl) 13001 ± 1207 12029 ±1500 0.619 11963 ± 1424 2493 ± 1854 <0.0001 
Glucose iAUC120-240 
(mg*min/dl) 20241 ± 1794 18135 ±2580 0.138 17505 ± 2721 13397 ± 2841 0.051 
Glucose incremental peak 
(mg/dl) 200 ±29 171 ±47 0.070 181 ± 46 150 ± 63 0.011 
Glucose time-to-peak (min) 132 ± 41 135 ± 29 0.85 128 ± 31 221 ± 32 <0.001 
Notes: Data are means (SD) unless otherwise indicated. p-values in boldface are significant. A
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